- mmahomed2
Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammatory product that is designed for intra-articular administration. Specifically, we will evaluate the efficacy of our drug to prevent post-traumatic osteoarthritis following joint injuries